Stanislas VEILLET – PhD, – Chairman – CEO
Stanislas Veillet created Biophytis in September 2006. He previously held a number of positions in the fields of medical research, nutrition and functional foods, in particular with Danone, Pharmacia-Monsanto and Cargill. Stanislas has a doctorate in genetics, graduated in engineering from AgroParisTech and has authored a dozen patents.
Jean-Christophe MONTIGNY – Chief Operating Officer
Jean-Christophe Montigny is an engineering graduate of AgroParisTech, has a BA degree from Sciences-Po Paris, and is a specialist in growth projects. Over a 15-year period he held several positions the finance and business development with the Kraft Foods group (which subsequently became Mondelez). He then co-founded the Below the Line Observatory, in the sector of data mining. He has been supervising the finance and legal functions of Biophytis since 2009.
Pr. René LAFONT – Chief Scientific Officer
Co-founder of the company with Stanislas Veillet, René Lafont is a biochemist (Ecole Normale Supérieure), Professor Emeritus at Sorbonne Université (formerly University Pierre et Marie Curie) and former Dean of the Department of Life Sciences. He has authored over 170 scientific publications and a dozen patents, he is also notably a Chevalier de l’Ordre des Palmes Académiques and a Laureate of the Karlson Foundation (Germany).
Doctor in Medicine (The Hebrew University of Jerusalem) and holder of two PhDs in neurology and biostatistics from the Tel Aviv university, Samuel Agus has over 15 years of experience in the pharmaceutical industry. He has held leading positions and has a proven track record in clinical development within biotech and leading pharmaceutical companies such as Teva Pharmaceuticals Industries, Solvay Pharmaceuticals then Abbott Laboratories, Shire Pharmaceuticals and Lundbeck. Since April 2017, he has been Vice President of Hansa Medical AB. An American-Israeli citizen, Samuel Agus specializes in the field of neurology and disorders related to neurodegeneration. He is also a specialist in rare diseases, such as DMD.
DANIEL SCHNEIDERMAN – CHIEF FINANCIAL OFFICER BIOPHYTIS Inc
Daniel Schneiderman served as Vice President of Finance and Controller of MetaStat, Inc., a Boston-based precision medicine company focused on developing novel anti-metastatic medications for patients with aggressive cancer. Prior to joining MetaStat in 2012, Mr. Schneiderman was Vice President of Investment Banking for Burnham Hill Partners where he worked from 2004. Mr. Schneiderman began his investment banking career at H.C. Wainwright & Co., Inc. as an Analyst. Mr. Schneiderman holds a Bachelor’s Degree in Economics from Tulane University.
Waly DIOH – PhD – VP Clinical Operations
With a doctorate in phytopathology (Paris XI), Waly Dioh spent most of his career with R&D teams in Monsanto, initially in France to set up a genotyping platform and then in the United States (Saint Louis – Missouri) where he ran a regulatory affairs team for the development of biotechnology products. He joined Biophytis at the inception and manages current clinical trials.
PhD in Pharmacology (Paris V University), Dr. Dilda has more than 20 years of experience in pharmaceutical research, in both academic and industrial settings (Mayoli Spindler Laboratories). Before joining Biophytis in December 2015, he was Senior Research Fellow at the Lowy Cancer Research Center at the University of New South Wales (UNSW) in Sydney, Australia, where he was responsible for advancing several cancer therapeutics.
Philippe has a doctorate in Pharmacy (Paris XI University) completed by an Executive‐MBA from ESSEC. He made his career within the pharmaceutical group Lavipharm before joining Opodex Industrie and more recently, Novagali Pharma (Santen group). He joined Biophytis in July 2015 to manage the projects, the regulatory studies and production of the company’s candidates
Doctor of Medicine (Ludwig-Maximilians-Universität, Munich), PhD in allergology, and an MBA graduate from INSEAD, Manfred Horst spent more than 25 years in the pharmaceutical industry holding multiple strategic positions at Ciba-Geigy/Novartis and serving as CEO of Mercur Value Health Gesundheitspartner (Allianz Group). Prior to joining Biophytis, Manfred Horst was Business Development Director Europe at MSD (Merck & Co.) from 2004 to 2016, where he contributed to numerous licensing agreements.